Actively Recruiting
The Outcome of Chronic Kidney Disease Patients With Obstructive Sleep Apnea Syndrome
Led by Nanfang Hospital, Southern Medical University · Updated on 2025-11-17
356
Participants Needed
1
Research Sites
232 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Obstructive sleep apnea (OSA) is highly prevalent in chronic kidney disease (CKD) patients and strongly linked to obesity, metabolic syndrome, and type 2 diabetes. Besides elevating cardiovascular disease risk, OSA may worsen renal function and diminish quality of life, making its understanding critical for CKD patient health. This study will establish a large, long-term cohort of non-dialysis CKD patients to identify OSA risk factors, explore OSA's association with adverse renal outcomes, and determine OSA prevalence and epidemiological characteristics within the CKD population. The findings will provide a scientific foundation for early OSA identification, diagnosis, and intervention in CKD patients.
CONDITIONS
Official Title
The Outcome of Chronic Kidney Disease Patients With Obstructive Sleep Apnea Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily sign the informed consent form
- Aged 18 years or older and less than 75 years
- Patients with CKD stages 3-4, with an eGFR of 15-60 ml/min/1.73m² calculated using the CKD-EPI formula for at least 3 months
You will not qualify if you...
- Patients receiving oxygen therapy or continuous positive airway pressure (CPAP) treatment
- Patients with other sleep disorders, including restless legs syndrome, periodic limb movement disorder, etc.
- Patients with severe heart failure (NYHA class III or IV)
- Patients with a myocardial infarction, unstable angina, or stroke within the past 3 months
- Patients with severe arrhythmias requiring medication or device therapy
- Patients with respiratory diseases, including COPD, asthma, thoracic deformities, etc.
- Patients with neurological disorders, including myasthenia gravis, Parkinson's disease, Alzheimer's disease, etc.
- Patients with active liver disease or severe hepatic insufficiency
- Patients with psychiatric conditions, including depression, anxiety disorders, etc.
- Patients with a history of malignancy within the past 5 years (except cured basal cell carcinoma)
- Patients with uncontrolled hyperthyroidism
- Patients who underwent surgery or had acute infections within the past 3 months
- Current heavy alcohol consumption: Females: >3 drinks/day or >7 drinks/week; Males: >4 drinks/day or >14 drinks/week
- Current use of medications that may severely interfere with sleep, such as antipsychotics, antiepileptics, antiparkinsonian drugs, antidepressants, opioids, etc.
- Females who are pregnant or lactating at screening or baseline
- Inability to comply with the study due to low education level, language barriers, inability to tolerate or complete sleep monitoring, or other reasons preventing completion of study procedures
- Deemed unsuitable for participation by the investigator's judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 518000
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here